FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hak Choy

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Natalie L Ausborn; Jeffrey D Bradley; Hak Choy; Adam P Dicker; Quynh-Thu Le; Debabrata Saha; Jeff Simko; Michael D Story; Artour Torossian; Bo Lu
Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Dong Wook Kim; Yu Shyr; Heidi Chen; Wallace Akerley; David H Johnson; Hak Choy
Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.
Dong Wook Kim; Yu Shyr; Bashar Shaktour; Wallace Akerley; David H Johnson; Hak Choy
Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hak Choy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Natalie L Ausborn; Jeffrey D Bradley; Hak Choy; Adam P Dicker; Quynh-Thu Le; Debabrata Saha; Jeff Simko; Michael D Story; Artour Torossian; Bo Lu
Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
International journal of radiation oncology, biology, physics 2012;83(4):e453-64.
2005: Dong Wook Kim; Yu Shyr; Heidi Chen; Wallace Akerley; David H Johnson; Hak Choy
Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.
International journal of radiation oncology, biology, physics 2005;63(4):1029-36.
2005: Dong Wook Kim; Yu Shyr; Bashar Shaktour; Wallace Akerley; David H Johnson; Hak Choy
Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;50(2):235-45.
2005: Hak Choy; Abdenour Nabid; Baldassarre Stea; Charles Scott; Wilson Roa; Lawrence Kleinberg; Joseph Ayoub; Colum Smith; Luis Souhami; Solomon Hamburg; William Spanos; Harvey Kreisman; Adam P Boyd; Pablo J Cagnoni; Walter Curran
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5918-28.
2005: Wallace Akerley; James E Herndon; Alan P Lyss; Hak Choy; Andrew T Turrisi; Stephen Graziano; Todd Williams; Chunfeng Zhang; Everett E Vokes; Mark R Green
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
Clinical lung cancer 2005;7(1):47-53.
2005: Karen L Tedesco; Jordan Berlin; Mace Rothenberg; Hak Choy; Ken Wyman; Adrian Scott Pearson; Robert Daniel Beauchamp; Nipun Merchant; A Craig Lockhart; Yu Shyr; Carol Caillouette; Bapsi Chakravarthy
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;76(1):54-8.
2005: Karen L Tedesco; Jordan Berlin; Charles D Blanke; Ming Teng; Hak Choy; John Roberts; R Daniel Beauchamp; Steven D Leach; Ken Wyman; John L Tarpley; Yu Shyr; Carol Caillouette; Bapsi Chakravarthy
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
International journal of radiation oncology, biology, physics 2005;61(5):1364-70.
2004: Bo Lu; Ling Geng; Amy Musiek; Jiahui Tan; Carolyn Cao; Edwin F Donnelly; Gerald McMahon; Hak Choy; Dennis E Hallahan
Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.
International journal of radiation oncology, biology, physics 2004;58(3):844-50.
2004: Rebecca Weinberg; Darryl G L Kaurin; Hak Choy; Walter Curran; Robert MacRae; Jae Sung Kim; Jaechul Kim; Susan L Tucker; Philip D Bonomi; Chandra P Belani; George Starkschall
Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study.
Journal of applied clinical medical physics / American College of Medical Physics 2004;5(4):15-28.
2004: Howard Safran; Thomas A DiPetrillo; Ahmed Nadeem; Margaret Steinhoff; Umadevi Tantravahi; ritesh rathore; Harold J Wanebo; Marilyn Hughes; Chris Maia; James Y Tsai; Terry Pasquariello; John R Pepperell; William G Cioffi; Teresa Kennedy; LAURIE REEDER; Thomas Ng; Alyn Adrian; Lisa Goldstein; Bapsi Chak; Hak Choy
Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study.
Cancer investigation 2004;22(5):670-7.
2004: Dong Wook Kim; Hak Choy
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
International journal of radiation oncology, biology, physics 2004;59(2 Suppl):11-20.
2003: Debabrata Saha; SEKHAR KONJETI; Carolyn Cao; Jason D Morrow; Hak Choy; Michael L Freeman
The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity.
Cancer research 2003;63(20):6920-7.
2003: Jae-Chul Kim; Jae-Sung Kim; Debabrata Saha; Qianwen Cao; Yu Shyr; Hak Choy
Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2003;68(3):305-13.
2003: Hak Choy; Dong W Kim
Chemotherapy and irradiation interaction.
Seminars in oncology 2003;30(4 Suppl 9):3-10.
2003: Debabrata Saha; Hong Ryull Pyo; Hak Choy
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
American journal of clinical oncology 2003;26(4):S70-4.
2003: Robert MacRae; Hak Choy
Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer.
Current oncology reports 2003;5(4):313-7.
2003: Debabrata Saha; Hak Choy
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
Progress in experimental tumor research 2003;37():193-209.
2002: Hong-Gyun Wu; Hak Choy
Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2002;16(9 Suppl 9):13-8.
2002: Rob MacRae; Yu Shyr; David Johnson; Hak Choy
Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(1):37-40.
2002: Christopher D Roman; Hak Choy; Lillian B Nanney; Colin Riordan; Kelly Parman; David Johnson; R Daniel Beauchamp
Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
The Journal of surgical research 2002;105(1):43-7.
2002: Jae Sung Kim; George P Amorino; Hong Ryull Pyo; Qianwen Cao; Hak Choy
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;62(1):61-7.
2001: Hak Choy; Russell F DeVore; Kenneth R Hande; LL Porter; PA Rosenblatt; Bonnie S Slovis; K LaPorte; Yu Shyr; D H Johnson
Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.
Lung cancer (Amsterdam, Netherlands) 2001;34(3):441-9.
2001: Hong Ryull Pyo; Hak Choy; George P Amorino; J S Kim; Q Cao; SK Hercules; Raymond DuBois
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):2998-3005.
2001: Jae Sung Kim; George P Amorino; Hong Ryull Pyo; Qianwen Cao; James O Price; Hak Choy
The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells.
International journal of radiation oncology, biology, physics 2001;51(2):525-34.
2001: John R Roberts; C Eustis; Russell F DeVore; D Carbone; Hak Choy; D Johnson
Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer.
The Annals of thoracic surgery 2001;72(3):885-8.
2001: George P Amorino; Haakil Lee; George E Holburn; Cynthia B Paschal; SK Hercules; Yu Shyr; R P Steffen; Hak Choy
Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13.
Radiation research 2001;156(3):294-300.
2001: Hak Choy; Rob MacRae
The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancer.
Seminars in oncology 2001;28(4 Suppl 14):17-22.
2001: Hak Choy; Rob MacRae
Irinotecan and radiation in combined-modality therapy for solid tumors.
Oncology (Williston Park, N.Y.) 2001;15(7 Suppl 8):22-8.
2001: Hak Choy; H Pyo; J S Kim; Rob MacRae
Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer.
Expert opinion on pharmacotherapy 2001;2(6):963-74.
2001: Hak Choy; J S Kim; H Pyo; Rob MacRae
Topoisomerase I inhibitors in the combined modality therapy of lung cancer.
Clinical lung cancer 2001;2 Suppl 2():S34-40.
2001: Hak Choy; Anuradha Chakravarthy; J S Kim
Radiation therapy for non-small cell lung cancer (NSCLC).
Cancer treatment and research 2001;105():121-48.
2001: Hak Choy; Rob MacRae
Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2001;15(1 Suppl 1):31-6.
2000: Hak Choy; Anuradha Chakravarthy; Russell F DeVore; Madan H Jagasia; Kenneth R Hande; John R Roberts; David H Johnson; F Yunus
Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 5):43-6.
2000: Hak Choy
Combination chemoradiotherapy with gemcitabine: potential applications.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 4):20-5.
2000: Hak Choy; Russell F DeVore; Kenneth R Hande; LL Porter; PA Rosenblatt; F Yunus; LL Schlabach; Colum Smith; Yu Shyr; David H Johnson
A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
International journal of radiation oncology, biology, physics 2000;47(4):931-7.
2000: George P Amorino; SK Hercules; PJ Mohr; Hong Ryull Pyo; Hak Choy
Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer.
International journal of radiation oncology, biology, physics 2000;47(2):503-9.
2000: Hak Choy; R F DeVore; Kenneth R Hande; LL Porter; PA Rosenblatt; Bonnie S Slovis; K LaPorte; Yu Shyr; David H Johnson
A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.
Clinical lung cancer 2000;1 Suppl 1():S27-31.
2000: George P Amorino; Michael L Freeman; Hak Choy
Enhancement of radiation effects in vitro by the estrogen metabolite 2-methoxyestradiol.
Radiation research 2000;153(4):384-91.
2000: Hak Choy; Yu Shyr; Anthony J Cmelak; PJ Mohr; David H Johnson
Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.
Cancer 2000;88(6):1336-46.
2000: George P Amorino; PJ Mohr; SK Hercules; Hong Ryull Pyo; Hak Choy
Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy.
Cancer chemotherapy and pharmacology 2000;46(5):423-6.
1999: Ming Teng; Hak Choy; David S Ettinger
Combined chemoradiation therapy for limited-stage small-cell lung cancer.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):107-15.
1999: Anuradha Chakravarthy; D Johnson; Hak Choy
The role of radiation, with or without chemotherapy, in the management of NSCLC.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):93-100.
1999: Michael Glantz; L Kim; Hak Choy; Wallace Akerley
Concurrent chemotherapy and radiotherapy in patients with brain tumors.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):78-82.
1999: Charles D Blanke; Ming Teng; Hak Choy
The role of UFT in combined-modality therapy.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):47-54.
1999: allan chen; Hak Choy; Mace L Rothenberg
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):39-46.
1999: Hak Choy
Taxanes in combined-modality therapy for solid tumors.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):23-38.
1999: George P Amorino; Michael L Freeman; David P Carbone; D E Lebwohl; Hak Choy
Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
International journal of radiation oncology, biology, physics 1999;44(2):399-405.
1999: Anthony J Cmelak; Hak Choy; Yu Shyr; PJ Mohr; M J Glantz; David H Johnson
National survey on prophylactic cranial irradiation: differences in practice patterns between medical and radiation oncologists.
International journal of radiation oncology, biology, physics 1999;44(1):157-62.
1999: Hak Choy; K LaPorte; E Knill-Selby; P Mohr; Yu Shyr
Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer.
Seminars in radiation oncology 1999;9(2 Suppl 1):90-6.
1999: Wallace Akerley; Hak Choy
Single-agent paclitaxel and radiation for non-small cell lung cancer.
Seminars in radiation oncology 1999;9(2 Suppl 1):85-9.
1999: Charles D Blanke; Hak Choy; Ming Teng; R Daniel Beauchamp; Steven D Leach; J Roberts; K Washington; D H Johnson
Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer.
Seminars in radiation oncology 1999;9(2 Suppl 1):43-52.
1999: Hak Choy; Wallace Akerley; Russell F DeVore
Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer.
Seminars in oncology 1999;26(1 Suppl 2):36-43.
1999: George P Amorino; V M Hamilton; Hak Choy
Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro.
Radiation oncology investigations 1999;7(6):343-52.
1998: Hak Choy; Wallace Akerley; Howard Safran; Stephen Graziano; C Chung; T Williams; B Cole; Teresa Kennedy
Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3316-22.
1998: Terek Wehbe; Michael Glantz; Hak Choy; LK Glantz; Selina C Cortez; Wallace Akerley; P Mills; B Cole
Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas.
Journal of neuro-oncology 1998;39(3):245-51.
1998: Hak Choy; Howard Safran; Wallace Akerley; Stephen Graziano; Jeffrey A. Bogart; Bernard F Cole
Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1931-6.
1998: Hak Choy; Wallace Akerley; Russell F DeVore
Paclitaxel, carboplatin and radiation therapy for non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 1998;12(1 Suppl 2):80-6.
1998: Steven J Hoff; JL Sawyers; Charles D Blanke; Hak Choy; J R Stewart
Prognosis of adenocarcinoma arising in Barrett's esophagus.
The Annals of thoracic surgery 1998;65(1):176-80; discussion 180-1.
1998: Wallace Akerley; Michael Glantz; Hak Choy; V Rege; Sundaresan Sambandam; P Joseph; L Yee; B Rodrigues; P Wingate; L Leone
Phase I trial of weekly paclitaxel in advanced lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):153-8.
1997: Hak Choy; Russell F DeVore; Kenneth R Hande; LL Porter; PA Rosenblatt; F Yunus; LL Schlabach; Colum Smith; Yu Shyr; K LaPorte; David H Johnson
Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 12):S12-21-S12-26.
1997: Wallace Akerley; Hak Choy; Howard Safran; William Sikov; V Rege; Sundaresan Sambandam; E Wittels
Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial.
Seminars in oncology 1997;24(4 Suppl 12):S12-10-S12-13.
1997: Michael Glantz; Hak Choy; L Yee
Prophylactic cranial irradiation in small cell lung cancer: rationale, results, and recommendations.
Seminars in oncology 1997;24(4):477-83.
1997: Howard Safran; T P King; Hak Choy; Paul J Hesketh; B Wolf; E Altenhein; William Sikov; Alan G Rosmarin; Wallace Akerley; Kathy Radie-Keane; G Cicchetti; F Lopez; Kirby I Bland; Harold J Wanebo
Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):901-7.
1996: Michael Glantz; Hak Choy; Wallace Akerley; C M Kearns; Merrill J Egorin; C Harker Rhodes; Bernard F Cole
Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response.
Seminars in oncology 1996;23(6 Suppl 16):128-35.
1996: Hak Choy; Wallace Akerley; Howard Safran; S Graziano; C Chung
Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer.
Seminars in oncology 1996;23(6 Suppl 16):117-9.
1996: Wallace Akerley; Michael Glantz; Hak Choy
Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer.
Seminars in oncology 1996;23(5 Suppl 12):14-8.
1996: Howard Safran; T King; Hak Choy; A Gollerkeri; H Kwakwa; F Lopez; B Cole; J Myers; J Tarpey; Alan G Rosmarin
p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.
Cancer 1996;78(6):1203-10.
1996: Michael Glantz; Bernard F Cole; M H Friedberg; E Lathi; Hak Choy; Karen L Furie; Wallace Akerley; L Wahlberg; A Lekos; S Louis
A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors.
Neurology 1996;46(4):985-91.
1996: Michael Glantz; Hak Choy; C M Kearns; Bernard F Cole; P Mills; Eleanor G Zuhowski; S Saris; C Harker Rhodes; Edward G Stopa; Merrill J Egorin
Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):600-9.
1995: Hak Choy; L Yee; Bernard F Cole
Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Seminars in oncology 1995;22(6 Suppl 15):38-44.
1995: Michael Glantz; Hak Choy; C M Kearns; Wallace Akerley; Merrill J Egorin
Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions.
Seminars in oncology 1995;22(5 Suppl 12):26-32.
1995: Hak Choy; Howard Safran
Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):55-7.
1995: Michael Glantz; Hak Choy; C M Kearns; P C Mills; L U Wahlberg; Eleanor G Zuhowski; P Calabresi; Merrill J Egorin
Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.
Journal of the National Cancer Institute 1995;87(14):1077-81.
1995: Michael Glantz; W A Hall; Bernard F Cole; B S Chozick; C M Shannon; L Wahlberg; Wallace Akerley; L Marin; Hak Choy
Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.
Cancer 1995;75(12):2919-31.
1995: Hak Choy; M J Browne
Paclitaxel as a radiation sensitizer in non-small cell lung cancer.
Seminars in oncology 1995;22(3 Suppl 6):70-4.
1995: Wallace Akerley; Hak Choy
Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 2():S107-15.
1994: Hak Choy; Wallace Akerley; Howard Safran; J Clark; V Rege; A Papa; Michael Glantz; Y Puthawala; C Soderberg; L Leone
Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2682-6.